We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds.
Humacyte, Inc. (NASDAQ:HUMA) is among the best penny stocks under $1 according to hedge funds
TheFly reported on May 14 that HUMA saw its price target increased at TD Cowen to $1.50 from $1.00 in a revised research update, with a Buy rating reiterated on the shares. The updated outlook followed the company’s first-quarter results, after which the model was adjusted. The outlook remains positive due to continued opportunity for Symvess in vascular trauma, along with longer-term growth potential from expansion into additional indications.
These include arteriovenous access, coronary artery bypass grafting, and peripheral artery disease, all of which represent larger overall addressable markets compared with the current use case. On May 13, Humacyte, Inc. (NASDAQ:HUMA) released its first-quarter 2026 financial results and business update for the period ended March 31, 2026. Commercial sales of Symvess totaled $0.5 million, or 29 units, compared with $0.1 million and five units in the prior-year quarter.